GRAIL reports Q3 results and receives favorable FDA advisory committee vote for Galleri
GRAIL Inc. posted third‑quarter 2026 revenue of $37.5 million, a 4% year‑over‑year increase, with Galleri test revenue of $37.3 million up 14% YoY. Test volume rose to more than 56,000, about 24% higher than a year earlier. The FDA’s Molecular and Clinical Genetics Panel voted in favor of Galleri’s approval, and the company expects a final FDA decision by early Q1 2027. GRAIL also raised its 2026 Galleri revenue growth outlook to 17%‑21%.
Why it matters
The company says an FDA approval would enable reimbursement and could accelerate revenue growth. The updated revenue growth guidance signals higher future cash flow, which may affect investor valuation.
Key facts
- 1Total Q3 2026 revenue was $37.5 million, up 4% YoY. prnewswire.com
- 2Galleri test revenue for Q3 grew 14% YoY to $37.3 million. prnewswire.com
- 3Galleri test volume for Q3 increased approximately 24% YoY to more than 56,000 tests. prnewswire.com
- 4Net loss for the quarter was $103.6 million. prnewswire.com
- 5Cash, cash equivalents and short‑term marketable securities totaled $788.7 million as of September 30 2026. prnewswire.com
- 6The FDA advisory committee voted in favor of Galleri’s approval, with a final decision expected by early Q1 2027. prnewswire.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.